Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Petrylak DP; Tangen CM; Hussain MH; Lara PN Jr; Jones JA; Taplin ME; Burch PA; Berry D; Moinpour C; Kohli M

doi:10.1056/nejmoa041318

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Identifier:nobleid.org/w1/20260526/E1AFBFEB

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/E1AFBFEB.svg?ark=w1%2F20260526%2FE1AFBFEB)](https://nobleid.org/work/w1/20260526/E1AFBFEB)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Identifier:nobleid.org/w1/20260526/E1AFBFEB

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/E1AFBFEB.svg?ark=w1%2F20260526%2FE1AFBFEB)](https://nobleid.org/work/w1/20260526/E1AFBFEB)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work